In vivo rat bladder: a new model to screen spasmolytic compounds

Area of Science:

• Pharmacology
• Urology
• Drug Discovery

Background:

• Screening spasmolytic compounds is crucial for treating bladder dysfunction.
• Existing in vitro models lack physiological relevance for absorption and metabolism.
• A need exists for a more comprehensive in vivo screening method.

Purpose of the Study:

• To develop and validate a physiological in vivo rat urinary bladder model for spasmolytic compound screening.
• To compare the efficacy of spasmolytic compounds in vivo versus in vitro.
• To assess the influence of administration route on drug efficacy.

Main Methods:

• Development of an in vivo rat urinary bladder model with optimal filling volume (0.6-1 ml).
• Comparison of spasmogenic effects of acetylcholine, KCl, and BaCl2 in vivo and in vitro.
• Evaluation of antagonistic effects of atropine, N-butylscopolammonium bromide, and flavoxate hydrochloride.
• Assessment of atropine's efficacy following intravenous and intragastric administration.

Main Results:

• The in vivo model demonstrated physiological relevance and specificity.
• Spasmogenic effects of agonists were comparable between in vivo and in vitro models.
• Antagonistic effects of tested compounds were directly comparable between models.
• Intravenous atropine showed immediate effect, while intragastric administration required 9 minutes for maximum effect.

Conclusions:

• The developed in vivo rat urinary bladder model is suitable for advanced screening of spasmolytic compounds.
• This model accounts for absorption, biotransformation, and excretion, offering a more complete assessment.
• It provides a valuable tool for preclinical drug development in urology.